Background: Rosacea-like papulopustular eruptions (rash) are considered the most frequent toxicities associated with the use of inhibitors of the epidermal growth factor receptor (EGFR). Recently, evidence has been accumulating of infectious complications in patients suffering from these adverse effects. Objective: We sought to analyze the density of Demodex folliculorum (DF) in cutaneous lesions of patients presenting with EGFR-inhibitor (EGFRI)-induced rashes. Methods: This is a retrospective study of 19 adult patients presenting with EGFRI rashes. Patients were reviewed for the density of DF (Demodex density, Dd; mites per square centimeter) by standardized skin surface biopsy. Results: In our patient collective the mean Dd of 4.7/cm2 significantly exceeded the mean Dd reported for the healthy adult population (Dd = 0.7/cm2). Limitations: The retrospective nature of the study. Conclusions: EGFRI patients have an increased susceptibility to DF colonization or infection, respectively. Our results support the recent concept that EGFRI may induce an impairment of antimicrobial defense mechanisms.

Keywords:
Epidermal growth factor receptor, adverse effect, Erlotinib, Gefitinib, Rash, Demodex mites, Infection
1.
Ciardiello F, Tortora G: EGFR antagonists in cancer treatment. N Engl J Med 2008;358:1160–1174.
2.
Jonker DJ, O’Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al: Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040–2048.
3.
Lacouture ME: Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006;6:803–812.
4.
Gerber PA, Buhren BA, Cevikbas F, Bölke E, Steinhoff M, Homey B: Preliminary evidence for a role of mast cells in epidermal growth factor receptor inhibitor-induced pruritus. J Am Acad Dermatol 2010;63:163–165.
5.
Gerber PA, Buhren BA, Homey B: More on aprepitant for erlotinib-induced pruritus. N Engl J Med 2011;364:486–487.
6.
Boone SL, Rademaker A, Liu D, Pfeiffer C, Mauro DJ, Lacouture ME: Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 2007;72:152–159.
7.
Agero AL, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC: Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006;55:657–670.
8.
Bonnar E, Eustace P, Powell FC: The Demodex mite population in rosacea. J Am Acad Dermatol 1993;28:443–448.
9.
Forton F, Germaux MA, Brasseur T, De Liever A, Laporte M, Mathys C, et al: Demodicosis and rosacea: epidemiology and significance in daily dermatologic practice. J Am Acad Dermatol 2005;52:74–87.
10.
Forton F, Seys B: Density of Demodex folliculorum in rosacea: a case-control study using standardized skin-surface biopsy. Br J Dermatol 1993;128:650–659.
11.
Marks R, Dawber RP: Skin surface biopsy: an improved technique for the examination of the horny layer. Br J Dermatol 1971;84:117–123.
12.
Jacot W, Bessis D, Jorda E, Ychou M, Fabbro M, Pujol JL, et al: Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol 2004;151:238–241.
13.
Eilers RE Jr, Gandhi M, Patel JD, Mulcahy MF, Agulnik M, Hensing T, et al: Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J Natl Cancer Inst 2010;102:47–53.
14.
Grenader T, Gipps M, Goldberg A: Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity. Clin Lung Cancer 2008;9:59–60.
15.
Kardaun SH, van Duinen KF: Erlotinib-induced florid acneiform rash complicated by extensive impetiginization. Clin Exp Dermatol 2008;33:46–49.
16.
Li J, Peccerillo J, Kaley K, Saif MW: Staphylococcus aureus bacteremia related with erlotinib skin toxicity in a patient with pancreatic cancer. JOP 2009;10:338–340.
17.
Lin WL, Lin WC, Yang JY, Chang YC, Ho HC, Yang LC, et al: Fatal toxic epidermal necrolysis associated with cetuximab in a patient with colon cancer. J Clin Oncol 2008;26:2779–2780.
18.
Rafailidis PI, Kakisi OK, Vardakas K, Falagas ME: Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials. Cancer 2007;109:2182–2189.
19.
Bolke E, Gerber PA, Lammering G, Peiper M, Muller-Homey A, Pape H, et al: Development and management of severe cutaneous side effects in head-and-neck cancer patients during concurrent radiotherapy and cetuximab. Strahlenther Onkol 2008;184:105–110.
20.
Gridelli C, Maione P, Amoroso D, Baldari M, Bearz A, Bettoli V, et al: Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel Meeting. Crit Rev Oncol Hematol 2008;66:155–162.
21.
Cholongitas E, Pipili C, Ioannidou D: Malassezia folliculitis presented as acneiform eruption after cetuximab administration. J Drugs Dermatol 2009;8:274–275.
22.
Forton F, Song M: Limitations of standardized skin surface biopsy in measurement of the density of Demodex folliculorum: a case report. Br J Dermatol 1998;139:697–700.
23.
Kocak M, Yagli S, Vahapoglu G, Eksioglu M: Permethrin 5% cream versus metronidazole 0.75% gel for the treatment of papulopustular rosacea: a randomized double-blind placebo-controlled study. Dermatology 2002;205:265–270.
24.
Schaller M, Sander CA, Plewig G: Demodex abscesses: clinical and therapeutic challenges. J Am Acad Dermatol 2003;49:S272–274.
25.
Segaert S, Van Cutsem E: Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005;16:1425–1433.
26.
Persi A, Rebora A: Metronidazole and Demodex folliculorum. Acta Derm Venereol 1981;61:182–183.
27.
Banuls J, Ramon D, Aniz E, Jorda E, Torres V: Papular pruritic eruption with human immunodeficiency virus infection. Int J Dermatol 1991;30:801–803.
28.
Dominey A, Rosen T, Tschen J: Papulonodular demodicidosis associated with acquired immunodeficiency syndrome. J Am Acad Dermatol 1989;20:197–201.
29.
Aquilina C, Viraben R, Sire S: Ivermectin-responsive Demodex infestation during human immunodeficiency virus infection: a case report and literature review. Dermatology 2002;205:394–397.
30.
Redondo Mateo J, Soto Guzman O, Fernandez Rubio E, Dominguez Franjo F: Demodex-attributed rosacea-like lesions in AIDS. Acta Derm Venereol 1993;73:437.
31.
Mascia F, Mariani V, Girolomoni G, Pastore S: Blockade of the EGF receptor induces a deranged chemokine expression in keratinocytes leading to enhanced skin inflammation. Am J Pathol 2003;163:303–312.
32.
Gerber PA, Enderlein E, Homey B: The Koebner-phenomenon in epidermal growth factor receptor inhibitor-induced cutaneous adverse effects. J Clin Oncol 2008;26:2790–2792.
33.
Basti S: Ocular toxicities of epidermal growth factor receptor inhibitors and their management. Cancer Nurs 2007;30:S10–16.
34.
Gerber PA, Homey B: Images in clinical medicine: erlotinib-induced hair alterations. N Engl J Med 2008;358:1175.
35.
Kheirkhah A, Casas V, Li W, Raju VK, Tseng SC: Corneal manifestations of ocular demodex infestation. Am J Ophthalmol 2007;143:743–749.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.